ShangPharma Buys Charles River’s Shanghai Lab
October 24, 2011 at 07:12 AM EDT
ShangPharma acquired the Shanghai research facility formerly owned by Charles River Labs. The purchase will allow ShangPharma’s main subsidiary, Shanghai ChemPartner, to expand its GLP tox study capacity. The lab comprises 31,990 square feet of in-vivo research facilities, which were designed for GLP tox studies, plus another 13,885 square feet of lab and office space. More details.... Stock Symbols: (NYSE: SHP) (NYSE: CRL)